A study of a new treatment for acquired hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new medicine called denecimig (Mim8) for adults newly diagnosed with a rare bleeding disorder called acquired hemophilia A. If you have had a bleed that needs treatment, this trial could help you manage your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (male or female) and have been newly diagnosed with acquired hemophilia A.
- Your factor VIII level is low (less than 50%) and you have a detectable inhibitor (more than 0.6 BU).
- You have had a bleed that required treatment because of the condition, from diagnosis until screening.
- You are not currently taking certain other immunosuppressant or immune-modulating drugs for this condition, except for very short-term (2 days or less) prednisolone at a low dose.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use highly effective birth control.
- You have no recent or current blood clot problems or high risk for them, and you are expected to live more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Inno8 in people with haemophilia A. It looks at how different doses work in the body and may help improve treatment options.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This study tests a new medicine called SKP-0141 to see if it can safely treat and prevent bleeding in people with severe hemophilia A. It might help reduce the number of bleeds and improve quality of life.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
Hear when a new Haemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.